Display Settings:

Format

Send to:

Choose Destination
    Genome Med. 2012 Jan 31;4(1):10.

    Drug transporter regulation in tumors by DNA methylation.

    Source

    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany. fromm@pharmakologie.med.uni-erlangen.de.

    Abstract

    Epigenetic alterations, such as aberrant DNA methylation, are a hallmark of cancer. DNA hypermethylation of the promoter region affects, for example, the expression of tumor suppressor genes and is associated with their transcriptional silencing in tumors. A recent report has provided evidence for epigenetic silencing of the multispecific organic cation transporter SLC22A1 in hepatocellular carcinoma. Given the role of this transporter in the cellular uptake of several anticancer drugs, the study provided a novel mechanism to explain the substantial variability in treatment response, and it might provide a new strategy for optimization of pharmacotherapy of hepatocellular carcinoma.See research article http://www.genomemedicine.com/content/3/12/82.

    PMID:
    22293136
    [PubMed - in process]
    PMCID:
    PMC3334558
    Free PMC Article

      Supplemental Content

      Icon for BioMed Central Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk